Literature DB >> 6153392

Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia.

D R Powars, W A Schroeder, J N Weiss, L S Chan, S P Azen.   

Abstract

Persons with sickle cell anemia who have elevated fetal hemoglobin or lowered erythrocyte mean corpuscular volume are reputed to have less severe clinical manifestations and a greater probability of survival. This study examines the relationship between seven clinical indicators of morbidity in sickle cell anemia and seven hematological parameters that were collected from 214 patients. Risks of sickle cell crisis, acute chest syndrome, hospital admissions, cerebrovascular accident, aseptic necrosis, meningitis/septicemia, and death were used as indicators of morbidity. The hematological parameters included percent fetal hemoglobin, absolute fetal hemoglobin, percent hemoglobin A2, hemoglobin concentration, packed cell volume, mean corpuscular volume, and mean corpuscular hemoglobin concentration. Statistical analyses of the data showed no relationship between the hematological parameters and six of the seven clinical indicators of the severity of sickle cell anemia. The only significant finding was an increased risk of stroke in those patients with lower levels of fetal hemoglobin. Therefore, with this exception, there is no predictable relationship between morbidity and mortality in sickle cell anemia and levels of fetal hemoglobin or erythrocyte indices. Thus, the general belief that there is an association between severity of sickle cell anemia and the levels of fetal hemoglobin has not been established.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6153392      PMCID: PMC371416          DOI: 10.1172/JCI109720

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

Review 1.  Human fetal hemoglobin: significance in disease.

Authors:  J F Bertles
Journal:  Ann N Y Acad Sci       Date:  1974-11-29       Impact factor: 5.691

2.  Iron-deficiency anemia and sickle-cell disease: a hypothesis.

Authors:  T L Lincoln; J Aroesty; P Morrison
Journal:  Lancet       Date:  1973-08-04       Impact factor: 79.321

3.  Mild sickle cell disease. Clinical and laboratory studies.

Authors:  M H Steinberg; B J Dreiling; F S Morrison; T F Necheles
Journal:  JAMA       Date:  1973-04-16       Impact factor: 56.272

4.  Benign obstetric history in women with sickle-cell anaemia associated with -thalassaemia.

Authors:  A van Enk; A Lang; J M White; H Lehmann
Journal:  Br Med J       Date:  1972-12-02

5.  A new sickling disorder resulting from interaction of the genes for haemoglobin S and alpha-thalassaemia.

Authors:  D J Weatherall; J B Clegg; J Blankson; J R McNeil
Journal:  Br J Haematol       Date:  1969-12       Impact factor: 6.998

6.  Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia.

Authors:  J F Bertles; P F Milner
Journal:  J Clin Invest       Date:  1968-08       Impact factor: 14.808

7.  Hemoglobin interaction: modification of solid phase composition in the sickling phenomenon.

Authors:  J F Bertles; R Rabinowitz; J Döbler
Journal:  Science       Date:  1970-07-24       Impact factor: 47.728

8.  Milder variant of sickle-cell disease in Arabs in Kuwait associated with unusually high level of foetal haemoglobin.

Authors:  S A Ali
Journal:  Br J Haematol       Date:  1970-11       Impact factor: 6.998

9.  Erythrocyte Hb-S concentration. An important factor in the low oxygen affinity of blood in sickle cell anemia.

Authors:  M Seakins; W N Gibbs; P F Milner; J F Bertles
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

10.  Abnormal rheology of oxygenated blood in sickle cell anemia.

Authors:  S Chien; S Usami; J F Bertles
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

View more
  11 in total

1.  Fetal haemoglobin and early manifestations of homozygous sickle cell disease.

Authors:  K Bailey; J S Morris; P Thomas; G R Serjeant
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

Review 2.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Hematol Oncol Clin North Am       Date:  2010-02       Impact factor: 3.722

Review 3.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 4.  Current concerns in haematology. 1. Is the painful crisis of sickle cell disease a "steal" syndrome?

Authors:  G R Serjeant; R M Chalmers
Journal:  J Clin Pathol       Date:  1990-10       Impact factor: 3.411

5.  Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis.

Authors:  E Du; Monica Diez-Silva; Gregory J Kato; Ming Dao; Subra Suresh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

6.  Alpha thalassemia changes erythrocyte heterogeneity in sickle cell disease.

Authors:  C T Noguchi; G J Dover; G P Rodgers; G R Serjeant; S E Antonarakis; N P Anagnou; D R Higgs; D J Weatherall; A N Schechter
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

Review 8.  Sickle cell vasoocclusion: many issues and some answers.

Authors:  D K Kaul; R L Nagel
Journal:  Experientia       Date:  1993-01-15

9.  Heterogeneity of sickle-cell anemia based on a profile of hematological variables.

Authors:  D J Odenheimer; C F Whitten; D L Rucknagel; S A Sarnaik; C F Sing
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

10.  Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign.

Authors:  Abdulrahman Alsultan; Mohammed K Alabdulaali; Paula J Griffin; Ahmed M Alsuliman; Hazem A Ghabbour; Paola Sebastiani; Waleed H Albuali; Amein K Al-Ali; David H K Chui; Martin H Steinberg
Journal:  Br J Haematol       Date:  2013-11-13       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.